Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.

MLA

Rediti, Mattia, et al. “Immunological and Clinicopathological Features Predict HER2-Positive Breast Cancer Prognosis in the Neoadjuvant NeoALTTO and CALGB 40601 Randomized Trials.” Nature Communications, vol. 14, no. 1, Nov. 2023, pp. 1–18. EBSCOhost, https://doi.org/10.1038/s41467-023-42635-2.

APA

Rediti, M., Fernandez-Martinez, A., Venet, D., Rothé, F., Hoadley, K. A., Parker, J. S., Singh, B., Campbell, J. D., Ballman, K. V., Hillman, D. W., Winer, E. P., El-Abed, S., Piccart, M., Di Cosimo, S., Symmans, W. F., Krop, I. E., Salgado, R., Loi, S., Pusztai, L., & Perou, C. M. (2023). Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature Communications, 14(1), 1–18. https://doi.org/10.1038/s41467-023-42635-2

Chicago

Rediti, Mattia, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, et al. 2023. “Immunological and Clinicopathological Features Predict HER2-Positive Breast Cancer Prognosis in the Neoadjuvant NeoALTTO and CALGB 40601 Randomized Trials.” Nature Communications 14 (1): 1–18. doi:10.1038/s41467-023-42635-2.